CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
LOXO-305 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05134350
NCT05134350Phase 1Completed

A Phase 1, Open Label, Randomized, 2-Way Crossover, 3-Period Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of LOXO-305 in Healthy Adult Subjects

Loxo Oncology, Inc.·interventional·Posted Nov 24, 2021·Updated Jan 10, 2025

In Brief

A Phase 1 clinical trial evaluating LOXO-305 and Omeprazole for Healthy Volunteers. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 24, 2021
Enrollment StartFeb 6, 2020
Primary CompletionMar 23, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.6 years ago

Interventions

LOXO-305drug

LOXO-305 orally.

Omeprazoledrug

Omeprazole Orally.